Companies

Request More Information

Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Experts Commenting on This Company

 

Visit Company Website

View Company News




BioLife Solutions Inc.

TICKER: BLFS:OTCBB

BioLife Solutions Inc. develops, manufactures and markets hypothermic storage and cryopreservation freeze media products for cells, tissues and organs. The company's proprietary HypoThermosol and CryoStor platform of solutions are highly valued in the biobanking, drug discovery and regenerative medicine markets. BioLife's products are serum-free, protein-free, fully defined and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides academic and clinical researchers and commercial companies significant improvement in shelf life and post-preservation viability and function of cells, tissues and organs.


The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

Brian Marckx, Zacks Investment Research (3/31/14) "BioLife Solutions Inc.'s contract manufacturing business is expected to provide a source of near-term revenue and cash flow to help fund the further development and commercialization of the biopreservation media business, which is expected to provide the bulk of revenue and drive earnings for the long-term. We are maintaining our Outperform rating."

Jerry Isaacson, LifeSci Advisors (3/26/14) "On March 26, BioLife Solutions Inc. completed a series of steps that culminated in a public offering that raised $15.4M and uplisting of the company's shares to trade on the NASDAQ Capital Market, substantially improving the company's capital structure. In conjunction with the financing, BioLife converted the entirety of its $14.3M in debt, replacing the debt with equity and putting the company on the path to being cash-flow positive."

Henry McCusker, Scimitar Equity LLC (3/26/14) "BioLife Solutions Inc. has closed a public offering of units for gross proceeds of approximately $15.4M at a price of $4.30/unit, completed the conversion of $14.3M of debt into equity and received approval to list its common stock on the NASDAQ Capital Market. . .the offering opened at $4.30, which was down from the previous close of $5.24. Do the math, Buy!"

Brian Marckx, Zacks Small-Cap Research (2/14/14) "2013 was another record year for BioLife Solutions Inc., with revenue of $9M, up 58% from $5.7M in 2012, which was the previous best. 2013 revenue crushed management's guidance of $6.57M provided at the end of 2012. . .revenue has now increased sequentially for 13 of the last 14 quarters."

Brian Marckx, Zacks Small-Cap Research (1/29/14) "On Jan. 29, 2014, BioLife Solutions Inc. announced a 1-for-14 reverse stock split. The reverse split, along with the previously announced agreement with the two debt holders of the company's promissory notes to convert the notes to equity, is being done to meet the requirements for an uplisting of the stock to NASDAQ. . .we are maintaining our Outperform rating." -Zacks Small-Cap Research

more comments

PropThink, Seeking Alpha (1/21/14) "We believe that developments in the last few months have positioned BioLife Solutions Inc. for meaningful upside. . .the shift back to product revenue has allowed the company to accelerate its gross profit growth, and reinvest the proceeds back into its business. . .for long-term investors, BioLife's move back to $0.60 presents an attractive entry point ahead of the company's move to the NASDAQ. . .we believe that the long-term story at BioLife is fully intact, and that 2014 will be a key year for the company as it moves closer to operating profitability."

Jerry Isaacson, LifeSci Advisors (1/9/14) "BioLife Solutions Inc. just reported preliminary record revenue of $9M in 2013, an increase of 58% over 2012, which itself was double 2011 revenue. The company has carefully managed expenses and is operating with only narrow losses and approaching positive cash flow."

Henry McCusker, Scimitar Equity LLC (1/6/14) "BioLife Solutions Inc. puts forth guidance and preliminary revenue of $9M for FY13; this represents 58% growth over 2012. It was another great year for the company, made possible by executing both strategically and operationally."

The Life Sciences Report Interview with Brian Marckx (12/19/13) "BioLife Solutions Inc. makes biopreservation media for cells, tissues and organs. These solutions are used to maintain the viability of biological material during storage and transportation. Today, most of the biopreservation market is dominated by what are called home brews, or in-house solutions. BioLife has its own proprietary biopreservation media, and it has been doing very well. Revenue has been very strong over the last few quarters. In fact, BioLife set revenue records in 11 of the last 12 quarters, and the stock is up about 100% in the last six months, even with a very significant pullback during the month of November. BioLife also has a contract manufacturing business, which has been helping with revenue and cash flow. Its media products are being used in several clinical trials to preserve tissues and cells. The hope is that, when and if the products in trials get FDA approval and are commercialized, they could be big winners for BioLife Solutions. This company clearly has a lot of traction." More >

Henry McCusker, Scimitar Equity LLC (12/17/13) "BioLife Solutions Inc. is transforming to a better funded, upgraded listed, more sustainable and viable investment via a reverse split, with an offering. . .concurrent news will be the 'enriching blood' to keep the stock liquid and appreciating to stimulate a successful offering. I'd be a buyer!"

Brian Marckx, Zacks Small-Cap Research (11/14/13) "BioLife Solution Inc.'s contract manufacturing business is expected to provide a source of near-term revenue and cash flow to help fund the further development and commercialization of the biopreservation media business, which is expected to provide the bulk of revenue and drive earnings for the long-term. Its share price is up over 800% since our July 2012 initiation. Maintaining Outperform rating. Our price target has moved from $1/share to $1.20/share."

Brian Marckx, Zacks Small-Cap Research (8/12/13) "BioLife Solutions Inc. announced financial results for the second quarter ending June 30: The company extended what has been a recurring theme with revenue setting another all-time record (beating the $2.2M posted in Q1/13, which was the previous record) and revenue increasing for the 12th consecutive quarter. . .we are maintaining our Outperform recommendation. . .BioLife expects to benefit from the emerging field of regenerative medicine, which has recently experienced rapid growth."

The Life Sciences Report Interview with Brian Marckx (8/8/13) "BioLife Solutions Inc. develops biopreservation media for cells, tissues and organs. Biopreservation media are solutions used to maintain the viability of biological material such as cells (including stem cells), whole blood and tissues following removal from the body, during storage and transportation, and while undergoing handling, manipulation and processing by researchers engaged in regenerative medicine product development. It is estimated that demand for biopreservation media will grow at an annual rate of almost 20% for the next several years. BioLife expects to benefit from the emerging field of regenerative medicine (including cell therapy and tissue engineering), which has recently experienced rapid growth, largely as a result of recent advancements using stem cells to regenerate and repair tissues and organs, as well as to treat a number of diseases.

"Today most of the biopreservation market is dominated by 'home brews,' or in-house solutions. BioLife Solutions' products, based on independent testing, appear to offer certain advantages over these home brews in terms of performance, reliability, shelf life and in the overall preservation of the viability and stability of cells. BioLife has drawn on more than two decades of molecular research that focused on how chilling can damage cells. . .Financial performance has been very strong. The company set a new revenue record for the ninth straight time in Q1/13. The stock is up about 370% in the last 12 months and is up about 438% since I started covering the company in July 2012. My current price target is $0.90/share." More >

Brian Marckx, Seeking Alpha (5/17/13) "BioLife Solutions Inc.'s main focus is on the development and manufacture of biopreservation media products for cells, tissues and organs. . .BioLife's strategy is to build greater visibility and awareness of the benefits of its biopreservation products compared to the 'home-brews'. . .key advantages such as extended shelf-life and higher preserved-cell yields translate into reduced input costs and greater stability of finished products for customers in regenerative medicine, biobanking and drug discovery. . .Q1/13 gross margin was very strong at 52%. . .management continues to do a nice job of managing operating expenses while at the same time significantly growing revenue."

Ivan Deryugin, Seeking Alpha (4/11/13) "As BioLife Solutions Inc. continues to execute on its business plan and eventually move to the NASDAQ, expect visibility and analyst coverage to increase in tandem. The company's management has shown that it can deliver on the underlying business, and BioLife is steadily ramping up its sales force, expanding its customer base and moving towards sustained positive operating cash flow. . .the company's 2012 results, as well as its prospects for 2013, suggest that it's a risk worth taking."

Helix Investment Research, Seeking Alpha (10/12/12) "From what we have seen, BioLife Solutions Inc. is a risky, but promising company. Its products meet a clear need and it has inked deals with some of the world's largest life sciences companies. Its revenues are growing at a solid rate. . .the company is executing its strategic plan, and as its debt restructuring has given it several more years to strengthen its balance sheet and cash flows, we are confident that BioLife's best days are ahead of it."

fewer comments
Due to permission requirements, not all quotes are shown.

BioLife Solutions Inc. Content





Back to Top

Would you like additional information on Life Sciences Tools & Diagnostics companies?
YES
disable